BioSpace News Archive

Ology Bioservices Inc., announced today it has been awarded a contract to advance development of a cocktail of anti-botulinum neurotoxin monoclonal antibodies (mAb) by the Department of Defense (DOD) through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

HTG Molecular Diagnostics, Inc., a life science company whose mission is to advance precision medicine, announced that it has entered into a $10.0 million senior term loan agreement with Silicon Valley Bank, the bank of the world’s most innovative companies and their investors, to replace its existing senior credit facility.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, today announced that it intends to offer shares of its common stock in an underwritten public offering.

Texas nursing home chain using interventional analytics solution to identify change in resident condition and intervene early to avoid hospital readmissions

In support of Mayo Clinic’s digital health and practice transformation initiatives, the Mayo Clinic Department of Laboratory Medicine and Pathology has initiated an enterprise-wide digital pathology implementation of the Sectra digital slide review and image storage and management system to enable digita

In response to the Senate health committee’s white paper on preparing for future pandemics, AACC sent a letter to committee leadership detailing four key steps the government should take to ready the U.S. for the next outbreak.

The U.S. Food and Drug Administration today approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. It is often characterized by severe and unrelenting

Durable Below-the-Knee Vascular Implant for Post-Angioplasty Dissection Repair Demonstrates Sustained Success Saving Limbs

Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its underwritten public offering of 12,506,811 shares of its common stock at a public offering price of $22.00 per share

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today.